

Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024

November 4, 2024

GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Tuesday, November 12, 2024. Details of the event and replay are as follows:

Conference call details:

Date:	November 12, 2024
Time:	8:30 a.m. U.S. ET
URL to register phone:	https://empportal.in/3Y6irHG
Dial-in number:	(800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International)
Webcast:	ir.novavax.com/events

- *Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.*
- *Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.*
- *To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.*

Replay details:

Date:	Available starting at 11:30 a.m. ET, November 12, 2024, until 11:59 p.m. U.S. ET, November 19, 2024
Dial-in number:	(888) 660-6345 (Domestic) or (+1) (646) 517-4150 (International)
Passcode:	62491 #
Webcast:	ir.novavax.com/events , until December 12, 2024

About Novavax

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and [LinkedIn](#) for more information.

Contacts:

Investors

Luis Sanay, CFA
240-268-2022
ir@novavax.com

Media

Giovanna Chandler
202-709-5563
media@novavax.com

SOURCE Novavax, Inc.